Fahimeh Fattahi

Dr. Fahimeh Fattahi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
FMFatemeh Mahmoudian
Fatemeh Mahmoudian
AAAzin Ahmari
Azin Ahmari
SSShiva Shabani
Shiva Shabani
BSBahman Sadeghi
Bahman Sadeghi
SFShohreh Fahimirad
Shohreh Fahimirad
FFFahimeh Fattahi
Fahimeh Fattahi
Conventional cancer treatments can cause serious side effects because they are not specific to cancer cells and can damage healthy cells. Aptamers often are single-stranded oligonucleotides arranged in a unique architecture, allowing them to bind specifically to target sites. This feature makes them an ideal choice for targeted therapeutics. They are typically produced through the systematic evolution of ligands by exponential enrichment (SELEX) and undergo extensive pharmacological revision to modify their affinity, specificity, and therapeutic half-life. Aptamers can act as drugs themselves, directly inhibiting tumor cells. Alternatively, they can be used in targeted drug delivery systems to transport drugs directly to tumor cells, minimizing toxicity to healthy cells. In this review, we will discuss the latest and most advanced approaches to using aptamers for cancer treatment, particularly targeted therapy overcoming resistance to conventional therapies.

10 March 2025 in Viruses
Verified
Journal Article
Open access
PDF file
MEMajid Eslami
Majid Eslami
NANeda Arjmand
Neda Arjmand
FMFatemeh Mahmoudian
Fatemeh Mahmoudian
ABAli Babaeizad
Ali Babaeizad
HTHamed Tahmasebi
Hamed Tahmasebi
Valentyn OksenychValentyn Oksenych
Valentyn Oksenych
Chronic viral infections like HIV, HBV, and HCV establish persistent interactions with the host immune system, resulting in immune evasion and long-term immune dysfunction. These viruses use a range of strategies to limit host defenses, such as downregulating MHC class I, disrupting interferon signaling, altering apoptosis pathways, and suppressing cytotoxic T-cell activity. Key viral proteins, including HIV Nef, HBV X protein, and HCV NS5A, interfere with antigen presentation and JAK/STAT signaling, thereby reducing antiviral immune responses. Chronic infections induce immune exhaustion due to persistent antigen exposure, which leads to the expression of inhibitory receptors like PD-1 and CTLA-4 on T cells. Viral epigenetic changes, such as N6-methyladenosine modifications and histone deacetylation, enhance immune evasion by modulating gene expression in infected cells. Viruses further manipulate host cytokine networks by promoting an immunosuppressive environment through IL-10 and TGF-β secretion, which suppress inflammatory responses and inhibit T-cell activation. This review examines the molecular/cellular mechanisms that enable chronic viruses to escape host immunity, focusing on antigenic variation, cytokine disruption, and control of apoptotic pathways. It also addresses how host genetic factors, such as HLA polymorphisms, influence disease progression. Lastly, we discuss host-targeted therapies, including immune checkpoint inhibitors, cytokine treatments, and CRISPR.

1 January 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
GEGolnaz Esfandiari
Golnaz Esfandiari
ABAzim S. Biranvand
Azim S. Biranvand
APAdeleh Poursaleh
Adeleh Poursaleh
NKNaser Kakavandi
Naser Kakavandi
FFFahimeh Fattahi
Fahimeh Fattahi
MNMohammad Najafi
Mohammad Najafi
Background: The Matrix Metalloproteinase (MMPs) secreted from macrophages can affect the extracellular matrix remodeling process and improve varicose veins. Aim: The aim of this study was to investigate the MMP-2 and MMP-9 gene expression and activity levels in the differentiated macrophages M2 of subjects with varicose veins, and to evaluate a peptide construct on their catalytic functions. Methods: The macrophages were differentiated from the monocytes using M-CSF. The MMP-2 and MMP-9 gene expression and activity levels were measured by RT-qPCR and Zymography techniques, respectively. A peptide construct (ESLCG) was predicted with bioinformatics tools, and was prepared for the study of enzyme functions as compared to Batimastat. Furthermore, the docking studies were obtained for the evaluation of interactions between peptide construct, Batimastat and enzyme 3D structures. Results: The results showed significant increases in MMP2 and MMP9 gene expression levels (P <0.001 and P <0.004, respectively) and gelatinolytic activities (P <0.001 and P <0.0001, respectively) in the macrophages. In agreement with the inhibitory effects of Batimastat, the peptide construct inhibited the MMP-2 and MMP-9 gelatinolytic activities up to 6.8 and 6.5 folds in the concentration of 150 µM. The docking analyses showed that the Lys187, Arg98, Leu49, Gly189, Leu190, Met97, Tyr53 and Phe57 residues of MMP-2 and the Leu187, His190, Glu402, His401, His405 and His411 residues of MMP-9 are interacted with the atoms of Batimastat and ESLCG peptide. Conclusion: The ESLCG peptide may be applied as an inhibitor of MMP-2 and MMP-9 enzymes in the subjects with varicose veins.

16 April 2019 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
MKMohsen Khosravi
Mohsen Khosravi
MNMohammad Najafi
Mohammad Najafi
AAAbdollah Amirfarhangi
Abdollah Amirfarhangi
MKMahdi Karimi
Mahdi Karimi
FFFahimeh Fattahi
Fahimeh Fattahi
MSMohammad Shabani
Mohammad Shabani
Atherosclerosis is developed due to the formation of atheroma plaques in the coronary arteries. In this process, M1 macrophages and vascular smooth muscle cells (VSMCs) are the main functional cells. Inflammatory mediators such as histamine may inflame M1 macrophages. The aim of this study was to determine the effect of M1 macrophage secretion contents on the gene and protein expression levels of focal adhesion kinase (FAK), vasodilator-stimulated phosphoprotein (VASP), and thrombospondin1 (THBS1). Whole blood samples from the six healthy subjects (stenosis70%) were prepared and peripheral blood mononuclear cells (PBMCs) were isolated. Then monocytes were differentiated into M1 macrophages using 100 ng/mL granulocyte-macrophage colony stimulating factor (GM-CSF). The differentiated M1 macrophages were treated with histamine (10-6 M), and their secretion contents were harvested and added to the culture medium of VSMCs. The FAK, VASP, and THBS1 gene expression and protein levels were measured using RT-qPCR and western blot techniques in VSMCs, respectively. The FAK and THBS1 gene expression levels significantly increased in VSMCs after adding secretion contents obtained from histamine-treated M1 macrophages (p=0.023 and 0.05, respectively), while significant results were not observed for VASP gene (p=0.45). In converse with the phosphorylated VASP (pVASP) (p<0.34), the phosphorylated FAK (pFAK) and THBS1 protein levels increased in VSMCs (p<0.001). We concluded that in inflammatory conditions, the immune events could affect the macrophages by histamine. The activated macrophages could locally activate signaling pathways via FAK and THBS1 genes that are effective in the proliferation and migration of VSMCs.

19 August 2026 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
FMFatemeh Mahmoudian
Fatemeh Mahmoudian
AAAzin Ahmari
Azin Ahmari
SSSomayeh Shamlou
Somayeh Shamlou
GAGlavizh Adibhesami
Glavizh Adibhesami
FAFatemeh Aboutalebi
Fatemeh Aboutalebi
JKJafar Kiani
Jafar Kiani